PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma: A STROBE compliant article.

Abstract Scavenger receptor class B type I (SR-B1) is highly expressed in a variety of cancers, including prostate, breast and ovarian. However, the relationship between SR-B1 and lung adenocarcinoma is unknown. We analyzed the expression of SR-B1 in a well-characterized lung adenocarcinoma tissue microarray by immunohistochemistry, in 90 cancerous and 90 adjacent normal lung tissues. Results showed that the positive expression rate of SR-B1 in cancer tissues (86/90, 96%) was significantly higher than that of adjacent tissues (50/90, 56%) (P < .001). And SR-B1 overexpression in lung adenocarcinoma tissue was significantly higher than that of adjacent normal tissue (P < .001), accounting for 67% of cases. This elevated SR-B1 expression was associated with AJCC stage (P < .001), T stage (P = .012), N stage (P = .002), and lymph node positivity (P < .001). The Kaplan-Meier survival analysis indicated that patients with high SR-B1 expression had a shorter overall survival (P < .001). On the multivariate analysis, SR-B1 was an independent prognostic factor for outcomes after adjustment for other prognostic factors (P = .038). In conclusion, high SR-B1 expression is associated with conventional pathologic parameters that represent tumor aggressiveness and may purport a poor clinical prognosis in lung adenocarcinoma.
PMID
Related Publications

Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging.

Correlation between expression of long non-coding RNA ZXF1 and prognosis of lung adenocarcinoma and its potential molecular mechanism.

Up-regulated expression of scavenger receptor class B type 1 (SR-B1) is associated with malignant behaviors and poor prognosis of breast cancer.

Low scavenger receptor class B type I expression is associated with gastric adenocarcinoma tumor aggressiveness.

High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29595658
OWN - NLM
STAT- MEDLINE
DCOM- 20180411
LR  - 20180411
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 13
DP  - 2018 Mar
TI  - High scavenger receptor class B type I expression is related to tumor
      aggressiveness and poor prognosis in lung adenocarcinoma: A STROBE compliant
      article.
PG  - e0203
LID - 10.1097/MD.0000000000010203 [doi]
AB  - Scavenger receptor class B type I (SR-B1) is highly expressed in a variety of
      cancers, including prostate, breast and ovarian. However, the relationship
      between SR-B1 and lung adenocarcinoma is unknown. We analyzed the expression of
      SR-B1 in a well-characterized lung adenocarcinoma tissue microarray by
      immunohistochemistry, in 90 cancerous and 90 adjacent normal lung tissues.
      Results showed that the positive expression rate of SR-B1 in cancer tissues
      (86/90, 96%) was significantly higher than that of adjacent tissues (50/90, 56%) 
      (P &lt; .001). And SR-B1 overexpression in lung adenocarcinoma tissue was
      significantly higher than that of adjacent normal tissue (P &lt; .001), accounting
      for 67% of cases. This elevated SR-B1 expression was associated with AJCC stage
      (P &lt; .001), T stage (P = .012), N stage (P = .002), and lymph node positivity (P 
      &lt; .001). The Kaplan-Meier survival analysis indicated that patients with high
      SR-B1 expression had a shorter overall survival (P &lt; .001). On the multivariate
      analysis, SR-B1 was an independent prognostic factor for outcomes after
      adjustment for other prognostic factors (P = .038). In conclusion, high SR-B1
      expression is associated with conventional pathologic parameters that represent
      tumor aggressiveness and may purport a poor clinical prognosis in lung
      adenocarcinoma.
FAU - Feng, Hong
AU  - Feng H
AD  - Department of Cancer Center.
FAU - Wang, Minghui
AU  - Wang M
AD  - Department of Cancer Center.
FAU - Wu, Changshun
AU  - Wu C
AD  - Department of Orthopedics, Shandong Provincial Hospital affiliated to Shandong
      University, Jinan, Shandong.
FAU - Yu, Jinyu
AU  - Yu J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Department of Renal Cancer and Melanoma, Peking University Cancer
      Hospital and Institute, Beijing.
FAU - Wang, Dan
AU  - Wang D
AD  - Central Laboratory, Shandong Provincial Hospital affiliated to Shandong
      University, 544 Jingsi Road, Jinan.
FAU - Ma, Jian
AU  - Ma J
AD  - Department of General Surgery, Yangxin County People's Hospital, Yangxin,
      Shandong, China.
FAU - Han, Junqing
AU  - Han J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Scavenger Receptors, Class B)
RN  - Adenocarcinoma of lung
SB  - AIM
SB  - IM
MH  - Adenocarcinoma/*pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Scavenger Receptors, Class B/*biosynthesis
MH  - Survival Analysis
EDAT- 2018/03/30 06:00
MHDA- 2018/04/12 06:00
CRDT- 2018/03/30 06:00
PHST- 2018/03/30 06:00 [entrez]
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2018/04/12 06:00 [medline]
AID - 10.1097/MD.0000000000010203 [doi]
AID - 00005792-201803300-00031 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Mar;97(13):e0203. doi: 10.1097/MD.0000000000010203.